VBWG
Slides

Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial



SPARCL

Download VBWG06_SPARCL.ppt (13 slides - 0.9MB)

SPARCL SPARCL: Background and rationale SPARCL: Study design SPARCL: Baseline characteristics SPARCL: Entry events SPARCL: Concomitant medications SPARCL: High-dose statin treatment reduces fatal/nonfatal stroke SPARCL: Treatment effect on stroke and TIA SPARCL: High-dose statin reduces majorcoronary events and stroke SPARCL: Reductions in major coronary events SPARCL: Adverse events SPARCL: Summary SPARCL: Implications


cholesterolPreventionSPARCLStroke

Related at vwbg.org

Expanding opportunities for secondary prevention of stroke

Between 1979 and 2001, the number of patients discharged from the hospital with a primary diagnosis of stroke increased by 25%.

Core Curriculum

Impact of vascular biology on cardiovascular disease, risk prevention, and treatment Section I: Atrial fibrillation, anticoagulation, and stroke prevention

The VBWG Core Curriculum 2004: Impact of vascular biology on cardiovascular disease, risk prevention, and treatment.

Vascular Biology in Clinical Practice © Vol. 5, No. 3

Atrial fibrillation and thromboembolism: Implications for stroke prevention

This monograph, Atrial fibrillation and thromboembolism: Implications for stroke prevention , is offered as part of a series of continuing medical education programs from the University of Florida College of Medicine.
More related